Oxygen for interstitial lung diseases

Exploring the effects of pulmonary rehabilitation and its determinants in lung transplant candidates with cystic fibrosis

BACKGROUND/RATIONALE

Lung transplant (LTx) candidates with cystic fibrosis (CF) have ventilatory and musculoskeletal limitations and benefit from pulmonary rehabilitation (PR). Their training response has not been well characterized. The study aims to: 1) characterize the effect of outpatient PR and 2) evaluate the clinical characteristics associated with their PR response.

METHODS

Single-center retrospective cohort study of CF LTx candidates (July 2009-June 2019) with available pre-transplant exercise data, who participated in PR 2 to 3 times/week until transplantation. Demographics, CF-related characteristics, aerobic and muscle training volumes, and six-minute walk distance (6MWD) were characterized using descriptive statistics, paired t-tests and Spearman correlations to describe relationships between CF-related characteristics and training volumes.

RESULTS

In 86 CF LTx candidates (32 ± 10 years, 49 % males, FEV1: 23 ± 5 %; listing 6MWD 421 ± 89 m), the median PR time was 87 days (24-36 sessions). 78 % had at least one exacerbation and 55 % required hospitalization. 88 % used supplemental oxygen and 37 % required home non-invasive ventilation. Treadmill speed (1.7 ± 0.5 mph); biceps (50 IQR [40-70] lbs∗reps) and quadriceps (30 IQR [30-40] lbs∗reps) training volumes improved with PR (p < 0.05), whereas 6MWD remained unchanged. The presence of ≥1 respiratory exacerbation was associated with a lower progression in treadmill speed [-0.36 mph 95%CI (-0.67 to -0.04), p = 0.028].

CONCLUSION

CF LTx candidates participating in PR increased treadmill speed and muscle training volumes, with preservation of 6MWD. Respiratory exacerbations were prevalent and important determinants of aerobic training.

Contemporary Concise Review 2022: Interstitial lung disease

Novel genetic associations for idiopathic pulmonary fibrosis (IPF) risk have been identified. Common genetic variants associated with IPF are also associated with chronic hypersensitivity pneumonitis. The characterization of underlying mechanisms, such as pathways involved in myofibroblast differentiation, may reveal targets for future treatments. Newly identified circulating biomarkers are associated with disease progression and mortality. Deep learning and machine learning may increase accuracy in the interpretation of CT scans. Novel treatments have shown benefit in phase 2 clinical trials. Hospitalization with COVID-19 is associated with residual lung abnormalities in a substantial number of patients. Inequalities exist in delivering and accessing interstitial lung disease specialist care.

A Retrospective, Descriptive Study of Dyspnea Management in a Multidisciplinary Interstitial Lung Disease Clinic

Background: Fibrotic interstitial lung diseases (F-ILDs) have a high symptom burden with progressive dyspnea as a primary feature. Breathlessness is underrecognized and undertreated primarily due to lack of consensus on how to best measure and manage it. Several nonpharmacologic and pharmacologic strategies are published in the literature, however there is a paucity of real-world data describing their systematic implementation. Objectives: We describe the types of breathlessness interventions and timing of implementation in our multidisciplinary collaborative care (MDC) ILD clinic and the impact of our approach on dyspnea trajectory and acute care use in ILD. Methods: A retrospective, observational study of deceased ILD patients seen in our clinic (2012-2018) was conducted. Patients were grouped by baseline medical research council (MRC) grade and dyspnea interventions from clinic enrolment until death were examined. Healthcare usage in the last 6 months of life was collected through Alberta's administrative database. Results: Eighty-one deceased ILD patients were identified. Self management advice was provided to 100% of patients. Pulmonary rehabilitation (PR) and home care (HC) referrals were made in 40% and 57% of patients, respectively. Eighty percent were treated with oxygen and 53% with opioids during the study. MDC-initiated referral to PR and HC, oxygen and opioid prescriptions were provided a median of 13, 9, 11, and 4 months prior to death, respectively. Stepwise implementation of interventions was observed more commonly in MRC 1-2 and concurrent implementation in MRC 4-5. Conclusions: Our clinic's approach allows early and systematic dyspnea management.

Management of Connective Tissue Disease-related Interstitial Lung Disease

Purpose of Review

This review aims to collate current evidence on the screening, diagnosis, and treatment of various connective tissue disease (CTD)-associated interstitial lung diseases (CTD-ILD) and present a contemporary framework for the management of such patients. It also seeks to summarize treatment outcomes including efficacy and safety of immunosuppressants, anti-fibrotics, and stem cell transplantation in CTD-ILD.

Recent Findings

Screening for ILD has been augmented by the use of artificial intelligence, ultra-low dose computerized tomography (CT) of the chest, and the use of chest ultrasound. Serum biomarkers have not found their way into clinical practice as yet. Identifying patients who need treatment and choosing the appropriate therapy is important to minimize the risk of therapy-related toxicity. The first-line drugs for systemic sclerosis (SSc) ILD include mycophenolate and cyclophosphamide. Nintedanib, an anti-fibrotic tyrosine kinase inhibitor, is approved for use in SSc-ILD. The US Food and Drug Administration (FDA) has recently approved tocilizumab subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with SSc-ILD. Autologous stem cell transplantation may have a role in select cases of SSc-ILD.

Summary

CTD-ILD is a challenging area with diverse entities and variable outcomes. High-resolution CT is the investigative modality of choice. Treatment decisions need to be individualized and are based on patient symptoms, lung function, radiologic abnormalities, and the risk of disease progression. Precision medicine may play an important role in determining the optimal therapy for an individual patient in the future.